A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease

Clinical Therapeutics

Volumn 27, Issue 11, 2005, Pages 1710-1724

  Chen, Jack J ^a   Obering, Crystal ^b  

^a LOMA LINDA UNIVERSITY   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Apomorphine; Fluctuations; Parkinson's disease; Subcutaneous

Indexed keywords

APOMORPHINE; CARBIDOPA; LEVODOPA;

ANGINA PECTORIS; CLINICAL TRIAL; DISEASE ASSOCIATION; DIZZINESS; DROWSINESS; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DYSKINESIA; EDEMA; HALLUCINATION; HUMAN; INJECTION SITE REACTION; MEDICAL RESEARCH; MEDLINE; MOTOR DYSFUNCTION; NAUSEA; PARKINSON DISEASE; REVIEW; RHINORRHEA; SIDE EFFECT; THORAX PAIN; VOMITING; YAWNING;

EID: 29144534690     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2005.11.016     Document Type: Article

References (43)

1. Chen J.J., and Shimomura S.K. Parkinsonism Herfindal E.T. Gourley D.R. The Textbook of Therapeutics: Drug and Disease Management 7th ed. 2000 Williams & Wilkins Baltimore, Md 1139 1155
2. Parkinson J. An essay on the shaking palsy 1817 Sherwood, Neely, and Jones London
3. Swope D.M. Rapid treatment of "wearing off" in Parkinson's disease Neurology 62 Suppl 4 2004 S27 S31
4. Pahwa R., and Lyons K.E. Options in the treatment of motor fluctuations and dyskinesias in Parkinson's disease: A brief review Neurol Clin 22 Suppl 3 2004 S35 S52
5. Matthiessen A., and Wright C.R. Research into the chemical constitution of the opium bases. Part I: On the action of hydrochloric acid on morphia Proc R Soc Lond B Biol Sci 17 1869 455 460
6. Weil E. De l'apomorphine dans certain troubles nerveux Lyon Med 48 1884 411 419
7. Schwab R.S., Amador L.V., and Lettvin J.Y. Apomorphine in Parkinson's disease Trans Am Neurol Assoc 56 1951 251 253
8. Cotzias G.C., Papavasiliou P.S., and Fehling C. Similarities between neurologic effects of L-dopa and of apomorphine N Engl J Med 282 1970 31 33
9. Stibe C.M., Lees A.J., Kempster P.A., and Stern G.M. Subcutaneous apomorphine in parkinsonian on-off oscillations Lancet 1 1988 403 406
10. LeWitt P.A. Subcutaneously administered apomorphine: Pharmacokinetics and metabolism Neurology 62 Suppl 4 2004 S8 S11
11. Goetz C.G., Koller W.C., and Poewe W. DA agonists-nonergot derivatives: Apomorphine Mov Disord 17 Suppl 4 2002 S83 S89
12. van der Geest R., van Laar T., and Kruger P.P. Pharmacokinetics, enantiomer interconversion and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease Clin Neuropharmacol 21 1998 159 168
13. Gancher S.T., Woodward W.R., Boucher B., and Nutt J.G. Peripheral pharmacokinetics of apomorphine in humans Ann Neurol 26 1989 232 238
14. Nicolle E., Pollak P., and Serre-Debeauvais F. Pharmacokinetics of apomorphine in parkinsonian patients Fundam Clin Pharmacol 7 1993 245 252
15. Neef C., and van Laar T. Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease Clin Pharmacokinet 37 1999 257 271
16. Goldman M.E., and Kebabian J.W. Aporphine enantiomers. Interactions with D-1 and D-2 dopamine receptors Mol Pharmacol 25 1984 18 23
17. Kempster P.A., Frankel J.P., Stern G.M., and Lees A.J. Comparison of motor response to apomorphine and levodopa in Parkinson's disease J Neurol Neurosurg Psychiatry 53 1990 1004 1007
18. Merello M., Pikielny R., Cammarota A., and Leiguarda R. Comparison of subcutaneous apomorphine versus dis persible madopar latency and effect duration in Parkinson's disease patients: A double-blind single-dose study Clin Neuropharmacol 20 1997 165 167
19. Dewey R.B. Jr, Hutton J.T., LeWitt P.A., and Factor S.A. A randomized, doubleblind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events Arch Neurol 58 2001 1385 1392
20. Pollak P., Champay A.S., and Hommel M. Subcutaneous apomorphine in Parkinson's disease J Neurol Neurosurg Psychiatry 52 1989 544
21. Poewe W., Kleedorfer B., Gerstenbrand F., and Oertel W. Subcutaneous apomorphine in Parkinson's disease Lancet 1 1988 943
22. Poewe W., Kleedorfer B., and Wagner M. Side-effects of subcutaneous apomorphine in Parkinson's disease Lancet 1 1989 1084 1085
23. Frankel J.P., Lees A.J., Kempster P.A., and Stern G.M. Subcutaneous apomorphine in the treatment of Parkinson's disease J Neurol Neurosurg Psychiatry 53 1990 96 101
24. Hughes A.J., Lees A.J., and Stern G.M. The motor response to sequential apomorphine in parkinsonian fluctuations J Neurol Neurosurg Psychiatry 54 1991 358 360
25. Hughes A.J., Bishop S., Stern G.M., and Lees A.J. The motor response to repeated apomorphine administration in Parkinson's disease Clin Neuropharmacol 14 1991 209 213
26. Hughes A.J., Bishop S., and Kleedorfer B. Subcutaneous apomorphine in Parkinson's disease: Response to chronic administration for up to five years Mov Disord 8 1993 165 170
27. Deffond D., Durif F., and Tournilhac M. Apomorphine in treatment of Parkinson's disease: Comparison between subcutaneous and sublingual routes J Neurol Neurosurg Psychiatry 56 1993 101 103
28. Gervason C.L., Pollak P.R., Limousin P., and Perret J.E. Reproducibility of motor effects induced by successive subcutaneous apomorphine injections in Parkinson's disease Clin Neuropharmacol 16 1993 113 119
29. Pietz K., Hagell P., and Odin P. Subcutaneous apomorphine in late state Parkinson's disease: A long term follow up J Neurol Neurosurg Psychiatry 65 1998 709 716
30. Hardie R.J., Lees A.J., and Stern G.M. On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study Brain 107 1984 487 506
31. Ostergaard L., Werdelin L., and Odin P. Pen injected apomorphine against off phenomena in late Parkinson's disease: A double blind, placebo controlled study J Neurol Neurosurg Psychiatry 58 1995 681 687
32. van Laar T., Jansen E.N., and Essink A.W. A double-blind study of the efficacy of apomorphine and its assess ment in 'off'-periods in Parkinson's disease Clin Neurol Neurosurg 95 1993 231 235
33. Abstract Sherry J.H., Guyton P.J., van Lunen B., and Bottini P.B. Continued efficacy and safety of subcutaneous injections of apomorphine in the treatment of off episodes in patients with Parkinson's disease Neurology 60 Suppl 1 2003 A81
34. Abstract Trosch R., and APO303 Investigators Decrease in UPDRS motor scores following intermittent subcu taneous apomorphine for 6 months in patients with advanced Parkinson's disease Mov Disord 19 Suppl 9 2004 2 217
35. Deleu D., Hanssens Y., and Northway M.G. Subcutaneous apomorphine: An evidence-based review of its use in Parkinson's disease Drugs Aging 21 2004 687 709
36. Bowron A. Practical considerations in the use of apomorphine injectable Neurology 62 Suppl 4 2004 S32 S36
37. Abstract Dewey R.B. Jr, and APO-401 Investigators Use of trimethobenzamide for the control of nausea in advanced Parkinson's disease patients treated with subcutaneous apomorphine Mov Disord 19 Suppl 9 2004 2 202
38. Baas H., Harder S., and Burklin F. Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations Clin Neuropharmacol 21 1998 86 92
39. Zijlmans J.C., Debilly B., and Rascol O. Safety of entacapone and apomorphine coadministration in levodopatreated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study Mov Disord 19 2004 1006 1011
40. Apokyn [package insert] April 2004 Mylan-Bertek Pharmaceuticals Research Triangle Park, NC
41. Manson A.J., Hanagasi H., and Turner K. Intravenous apomorphine therapy in Parkinson's disease: Clinical and pharmacokinetic observations Brain 124 2001 331 340
42. Dodel R.C., Berger K., and Oertel W.H. Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: Impact of motor fluctuations and dyskinesias Pharmacoeconomics 19 2001 1013 1038
43. Fleming T. 2005 Drug Topics Redbook Annual CD-ROM 2005 Thomson Healthcare Montvale, NJ